Impact of Bariatric Surgery on Pharmacokinetic Study of Simvastatin and Carvedilol
Status:
Enrolling by invitation
Trial end date:
2023-06-01
Target enrollment:
Participant gender:
Summary
This study aims to evaluate the influence of Roux-en Y gastric bypass bariatric surgery
(RYGB) on simvastatin and carvedilol kinetic disposition. Furthermore, the expression of
CYP3A4 and P-glycoprotein (mRNA) will be assessed in intestinal biopsies before, during and
after surgery. Patients with body mass index ≥ 35 kg/mˆ2 who have indication for RYGB
bariatric surgery are being investigated (n= 18 for simvastatin and n= 20 for carvedilol).
Phase:
Phase 4
Details
Lead Sponsor:
Natalia Valadares de Moraes
Collaborators:
Fundação de Amparo à Pesquisa do Estado de São Paulo University of Sao Paulo